Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WTX212A +/- PD-1/PD-L1 mAb in Advanced Lung Cancer
NCT06106152Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2023
- Primary completion
- Oct 2024
- Modality
- Antibody-Drug Conjugates (ADCs), Other Engineered Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of WTX212A in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Efficacy of WTX212A combined with PD-1/PD-L1 monoclonal antibody at 1 year. Started Dec 2023; status: recruiting.
02
Drugs
WTX212A
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06106152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06106152.